...
首页> 外文期刊>Biochimica et biophysica acta: BBA: International journal of biochemistry, biophysics and molecular biololgy. Proteins and Proteomics >Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase
【24h】

Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase

机译:ssDNA适体作为结核分枝杆菌乙酰羟酸合酶有效抑制剂的开发

获取原文
获取原文并翻译 | 示例

摘要

Acetohydroxyacid synthase (AHAS) from Mycobacterium tuberculosis (Mtb) is a promising potential drug target for an emerging class of new anti-tuberculosis agents. In this study, we identify short (30-mer) single-stranded DNA aptamers as a novel class of potent inhibitors of Mtb-AHAS through an in vitro DNA-SELEX method. Among all tested aptamers, two candidate aptamers (Mtb-Apt1 and Mtb-Apt6) demonstrated the greatest inhibitory potential against Mtb-AHAS activity with IC50 values in the low nanomolar range (28.94 +/- 0.002 and 2235 +/- 0.001 nM respectively). Interestingly, inhibition kinetics analysis of these aptamers showed different modes of enzyme inhibition (competitive and mixed type of inhibition respectively). Secondary structure-guided mutational modification analysis of Mtb-Apt1 and Mtb-Apt6 identified the minimal region responsible for their inhibitory action and consequently led to 17-mer and 20-mer shortened aptamers that retained equivalent or greater inhibitory potential. Notably, a modeling and docking exercise investigated the binding site of these two potent inhibitory aptamers on the target protein and showed possible involvement of some key catalytic dimer interface residues of AHAS in the DNA-protein interactions that lead to its potent inhibition. Importantly, these two short candidate aptamers, Mtb-Apt1 (17-mer) and Mtb-Apt6 (20-mer), also demonstrated significant growth inhibition against multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of tuberculosis with very low MIC of 536 mu g/ml and 6.24 mu g/ml, respectively and no significant cytotoxicity against mammalian cell line. This is the first report of functional inhibitory aptamers against Mtb-AHAS and provides the basis for development of these aptamers as novel and strong anti-tuberculosis agents. (C) 2015 Elsevier B.V. All rights reserved.
机译:来自结核分枝杆菌(Mtb)的乙酰羟酸合酶(AHAS)是新兴的新型抗结核药的有希望的潜在药物靶标。在这项研究中,我们通过体外DNA-SELEX方法将短(30-mer)单链DNA适体确定为一类新型的Mtb-AHAS强效抑制剂。在所有测试的适体中,两个候选适体(Mtb-Apt1和Mtb-Apt6)显示出对Mtb-AHAS活性的最大抑制潜力,IC50值在低纳摩尔范围内(分别为28.94 +/- 0.002和2235 +/- 0.001 nM) 。有趣的是,对这些适体的抑制动力学分析显示了不同的酶抑制模式(分别是竞争型和混合型抑制)。 Mtb-Apt1和Mtb-Apt6的二级结构指导的突变修饰分析确定了抑制它们的抑制作用的最小区域,因此导致17-mer和20-mer缩短的适体,保留了相同或更高的抑制潜力。值得注意的是,建模和对接练习研究了这两种有效抑制适体在靶蛋白上的结合位点,并显示了AHAS的一些关键催化二聚体界面残基可能参与了导致其有效抑制的DNA-蛋白质相互作用。重要的是,这两种短的候选适体,Mtb-Apt1(17-mer)和Mtb-Apt6(20-mer),也显示出对多药耐药性(MDR-TB)和广泛耐药性(XDR-TB)的显着生长抑制作用极低的MIC分别为536μg/ ml和6.24μg/ ml的结核病菌株,并且对哺乳动物细胞系没有明显的细胞毒性。这是针对Mtb-AHAS的功能性抑制性适体的首次报道,并为开发这些适体作为新型和强效抗结核药提供了基础。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号